## CLAIMS

1. A pharmaceutical composition comprising a nanoparticle composition, a botulinum toxin, and at least one excipient,

wherein the nanoparticle composition comprises a population of particles, wherein the majority of particles have diameters between 10 and 300 nanometers,

wherein the nanoparticle composition comprises at least one aqueous dispersion medium, at least one oil, and at least one surfactant,

wherein the oil is a medium chain triglyceride,

wherein the surfactant is a polysorbate,

wherein the ratio of oil to surfactant is between about 0.5:1 to about 1:1; and,

wherein the at least one excipient is mineral oil, isopropyl myristate, white petrolatum, emulsifying wax, propyl paraben, methylparaben, or any combination thereof,

wherein the pharmaceutical composition has a degree of transdermal penetration higher than when said at least one excipient is absent.

2. The pharmaceutical composition of claim 1, wherein the medium chain triglyceride is an acid containing 6-12 carbons atoms or is Labracfac Lipophile WL 1349 oil.

3. The pharmaceutical composition of claim 1, wherein the polysorbate is polysorbate 80.

4. The pharmaceutical composition of any one of claims 1-3, wherein the pharmaceutical composition does not contain parabens.

5. The pharmaceutical composition of claim 1, wherein the botulinum toxin is selected from the group comprising type A, type Ab, type Af, type B, type Bf, type Cl, type C2, type D, type E, type F, type G, and any combinations thereof, optionally the botulinum toxin is type A botulinum toxin.

6. The pharmaceutical composition of any one of claims 1-5, wherein the pharmaceutical composition remains stable following prolonged storage, wherein the prolonged storage is at least 1 week, at least 2 weeks, at least 1 month, at least 2 months, at least 3 months, at least 6 months, at least 9 months, or at least 12 months, optionally wherein the prolonged storage is carried out at 2 °C to 8 °C.

7. A kit comprising the pharmaceutical composition of any one of claims 1-5.

8. Use of the pharmaceutical composition of any one of claims 1-5 in the manufacture of an medicament for treatment of a condition or disorder selected from the group consisting of acne, hyperhidrosis, unwanted sweating, excess sebum-producing disorders, rosacea, psoriasis, dermal infections, actinic keratosis, eczematous dermatitis, burns, Raynaud's phenomenon, lupus erythematosus, hyperpigmentation disorders, skin cancer, and headache, and/or combinations thereof.

9. The use of claim 8, wherein the pharmaceutical composition is to be administered via a route of delivery selected from the group consisting of oral, rectal, vaginal, mucosal, intranasal, buccal, enteral, sublingual, and combinations thereof.

10. Use of the pharmaceutical composition of any one of claims 1-5, for treating a cosmetic condition selected from the group consisting of hair loss, facial wrinkles, wrinkles involving the forehead, glabellar, rhytids and/or periorbital regions, unsightly facial expressions, neck lines, hyperfunctional facial lines, hyperkinetic facial lines, and platysma bands.